In this issue:
Association of sustained immunotherapy with disability outcomes in patients with active SPMS
EBV infection after adolescence and HH6A as MS risk factors
Long-term follow-up of ocrelizumab for primary progressive multiple sclerosis
Examination of MOG antibody assays
Correlations between three upper limb objective measures in MS
Patient- vs physician-reported relapses in MS
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive MS
Long-term outcomes of CIS patients
Efficacy of alemtuzumab over 6 years in relapsing-remitting MS patients who relapsed between courses 1 and 2
Safety results of a shorter ocrelizumab infusion protocol for primary progressive and relapsing MS
Please login below to download this issue (PDF)